Sibutramine

Sibutramine, previously marketed under the brand name Meridia, functions as an appetite suppressant, albeit its usage has been discontinued across numerous nations.

Operating as a serotonin–norepinephrine reuptake inhibitor (SNRI), akin to certain tricyclic antidepressants, it was extensively prescribed until 2010 to complement dietary and exercise regimens in combating obesity.

However, its association with heightened risks of cardiovascular diseases and strokes prompted its removal from markets in various countries and territories, including the United States. Originally formulated in 1988, Sibutramine was categorized as a Schedule IV controlled substance in the US.